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Abstract
Human Herpesvirus 6 (HHV-6) is a ubiquitous virus with an estimated seroprevalence of 95% in the adult population. HHV-6
is associated with several neurologic disorders, including multiple sclerosis, an inflammatory demyelinating disease
affecting the CNS. Animal models of HHV-6 infection would help clarify its role in human disease but have been slow to
develop because rodents lack CD46, the receptor for cellular entry. Therefore, we investigated the effects of HHV-6
infections in a non-human primate, the common marmoset Callithrix jacchus. We inoculated a total of 12 marmosets with
HHV-6A and HHV-6B intravenously and HHV-6A intranasally. Animals were monitored for 25 weeks post-inoculation
clinically, immunologically and by MRI. Marmosets inoculated with HHV-6A intravenously exhibited neurologic symptoms
and generated virus-specific antibody responses, while those inoculated intravenously with HHV-6B were asymptomatic
and generated comparatively lower antibody responses. Viral DNA was detected at a low frequency in paraffin-embedded
CNS tissue of a subset of marmosets inoculated with HHV-6A and HHV-6B intravenously. When different routes of HHV-6A
inoculation were compared, intravenous inoculation resulted in virus-specific antibody responses and infrequent detection
of viral DNA in the periphery, while intranasal inoculation resulted in negligible virus-specific antibody responses and
frequent detection of viral DNA in the periphery. Moreover, marmosets inoculated with HHV-6A intravenously exhibited
neurologic symptoms, while marmosets inoculated with HHV-6A intranasally were asymptomatic. We demonstrate that a
marmoset model of HHV-6 infection can serve to further define the contribution of this ubiquitous virus to human
neurologic disorders.
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Introduction
Human Herpes Virus 6 (HHV-6) is a member of the Roseolovirus
genus of the b-herpesvirus subfamily [1]. Since its identification in
1986, two species, HHV-6A and HHV-6B, have been described
[2]. Though HHV-6A and HHV-6B share high sequence
homology, they differ in cellular tropism and clinical manifestation
[3,4,5,6] to the extent that they were recently reclassified as two
distinct viruses (International Committee on Taxonomy of
Viruses, 2011). Primary infection with HHV-6B is often associated
with febrile illness [7], and this virus is the etiologic agent of the
self-limiting childhood illness roseola infantum [8]. By contrast, the
symptoms associated with HHV-6A infection are largely un-
known.
HHV-6 is acquired during early childhood [7]. The virus has a
worldwide distribution, with an estimated seroprevalence of 95%
in the adult population [9,10]. HHV-6 cell tropism is notably
lymphotropic and neurotropic, though it can infect a wide range of
human cells in vitro due to the ubiquity of its major receptor, CD46
[11]. Similar to other herpesviruses, HHV-6 can establish lifelong
latent, asymptomatic infections [12]. However, the virus may
reactivate as a consequence of immunosuppression, manifesting
for example as a febrile illness [13] or encephalitis following bone
marrow [14] or solid organ [15] transplantation.
HHV-6 DNA has been reported in normal brain tissues [16]
suggesting that this virus may be a commensal of the brain under
some circumstances [17]. However, HHV-6 is also associated with
neurologic conditions including encephalitis [18] [19] [20],
temporal lobe epilepsy [21] [22] and multiple sclerosis (MS)
[23,24,25], findings that have been established by assessing both
the distribution of viral DNA and serologic responses. HHV-6
DNA is found in MS lesions [26] [27] [28]. Moreover, HHV-6
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and urine, of some MS patients [29], and is detected at higher
frequencies during periods of clinical exacerbation relative to
periods of remission. As HHV-6 is normally cell-associated, the
detection of viral DNA in cell-free compartments suggests an
active infection [30]. More recently, significantly elevated serum
HHV-6 IgM in MS patients versus controls was reported in an
Iranian population [31], and a positive, dose-dependent correla-
tion of serum HHV-6 IgG titers with MS relapse risk was reported
in an Australian MS cohort [32].
Despite the association of HHV-6 with several central nervous
system (CNS) disorders [33], [34], [19] it has been difficult to
prove causation in clinical disease. This is partly due to the
ubiquity of HHV-6 infection in the general population and also
because no animal model exists. Animal models of HHV-6
infection have been difficult to establish because rodents lack the
complement regulatory receptor, CD46, that HHV-6 uses for
cellular entry [35]. The common marmoset (C. jacchus) is a New
World non-human primate that naturally expresses CD46 [36]
and is therefore susceptible to infection with HHV-6.
Marmoset models of various neurologic diseases have been
developed [37], including the animal model for MS, experimental
autoimmune encephalomyelitis (EAE). EAE is an inflammatory,
demyelinating disease of the CNS induced by immunization with
myelin antigen(s) [38,39,40,41]. It is increasingly apparent that
marmoset EAE (relative to rodent EAE) has superior translational
applicability, due to greater similarities with MS such as CD8 T
cell involvement, the presence of both brain and spinal cord lesions
and importantly, the ability for MRI analysis of lesions [39].
Marmosets are particularly appropriate for studies involving MRI
monitoring because the cerebral organization resembles, but is
considerably simpler than that of humans. Moreover, these
primates are ideal models for studying the pathogenesis and host
response to a human virus in a non-human system due to their
genetic and immunologic proximity to humans, in addition to
their broad behavioral range [39]. Marmosets have been infected
with other human herpesviruses, such as Varicella Zoster virus
(VZV) [42], Kaposi’s sarcoma-associated herpesvirus (KSHV)
[43], as well as non-herpesviruses such as dengue virus (DENV)
[44].
In this study, marmosets were inoculated with HHV-6A or
HHV-6B intravenously, or with HHV-6A intranasally. Intranasal
inoculation was examined based on a recent report demonstrating
the olfactory pathway as a possible route of HHV-6 entry into the
CNS [45]. All resulting infections were monitored clinically,
immunologically and by MRI for 25 weeks following the first
inoculation. Previous work has demonstrated that following
intravenously administered HHV-6-infected cell lysates, marmo-
sets can develop hypotonic paralysis with sensory deficits
accompanied by weight loss (Genain, C., unpublished data, 6
th
international conference on HHV-6 & 7). Here we report that
marmosets inoculated intravenously with HHV-6A exhibit neu-
rologic symptoms, mount virus-specific IgM and IgG responses
and effectively clear the virus from peripheral circulation. By
contrast, marmosets inoculated intranasally with HHV-6A are
asymptomatic, do not mount virus-specific IgM or IgG responses
and fail to clear the virus from peripheral circulation within the
25-week monitoring period of this study. These observations
suggest that the route of inoculation is an important determinant
for establishing humoral immunity, and that humoral immunity
may influence not only the peripheral circulation of viral DNA,
but also pathological features such as clinical symptoms and CNS
pathology.
Methods
Animals
Fifteen adult common marmosets (Callithrix jacchus) (Table 1)
were used in this study. Marmosets were singly housed with a
twelve-hour light/dark cycle on a diet of Zupreem canned
marmoset food, Purina 5040 biscuits, fruit and vegetable treats
and ad libitum unfiltered water and PRANG rehydrator.
Ethics statement
All marmosets were housed at the National Institutes of Health
Intramural Research Program (PHS Assurance #A4149-01)
facilities in accordance with the standards of the American
Association for Accreditation of Laboratory Animal Care and the
National Institute of Neurological Disorders and Stroke’s Internal
Animal Care and Use Committee (NINDS IACUC). All
experiments adhered to a protocol that was reviewed and
approved by the NINDS IACUC.
Virus and infection
HHV-6A (U1102) and HHV-6B (Z29) were separately propa-
gated in the T-lymphoblastoid cell line SupT1 as described
previously [46]. The supernatants of infected cells were quantified
using real time PCR, with primers to detect the intermediate early
U90 region of the HHV-6 genome as described previously [47].
Supernatants were stored at 280uC until use. Marmosets were
anesthetized with ketamine (10 mg/kg) prior to viral inoculations.
Three groups of marmosets were injected intravenously with
HHV-6A supernatants (1610
9 viral copies of DNA) (n=4; M01–
M04), HHV-6B supernatants (1610
9 viral copies of DNA) (n=4;
M05–M08) or mock-infected supernatants from uninfected SupT1
cells (n=3; M09–M11) (Table 1). Marmosets were re-exposed
intravenously once a month for a total of four doses (4610
9 total
viral copies of DNA). A fourth group of marmosets was induced
with HHV-6A supernatant intranasally (2610
7 viral copies of
Author Summary
The human herpesviruses HHV-6A and HHV-6B are widely
distributed in the human population, but also specifically
associated with several central nervous system (CNS)
diseases. We investigated HHV-6A and HHV-6B infections
in the common marmoset, a non-human primate naturally
susceptible to infection, unlike rodents. We inoculated
marmosets with HHV-6A and HHV-6B intravenously, and
with HHV-6A intranasally, to represent a more physiologic
route of infection. Following intravenous HHV-6A inocula-
tion, marmosets exhibited clinical symptoms with evi-
dence of spinal cord pathology. Animals inoculated
intravenously with HHV-6B were asymptomatic and
without detectable CNS pathology. Both groups devel-
oped robust anti-viral antibody responses, and we detect-
ed viral DNA infrequently in the periphery. By contrast,
marmosets inoculated intranasally with HHV-6A were
asymptomatic, failed to generate anti-viral antibodies,
and we frequently detected viral DNA in the periphery.
Interestingly, HHV-6 DNA was detected in brain and spinal
cord sections of several intravenously inoculated animals,
demonstrating that HHV-6 can gain access to and persist
in the CNS. These observations help to define the
contributions of ubiquitous herpesviruses to neurologic
disease development in a non-human primate. As little is
known about the acquisition and host response to HHV-
6A, this model may clarify how this virus may trigger or
potentiate disease.
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intranasally once a month for a total of three doses (6610
7 total
viral copies of DNA).
Disease assessment
Following HHV-6 inoculation, all marmosets were monitored
and scored daily for signs of disease development. Clinical signs
were scored using a previously described semiquantitative scale
commonly used to assess marmoset EAE [48]. Briefly, 0: no
clinical signs; 0.5: apathy or altered walking pattern without
ataxia; 1: lethargy or tremor; 2: ataxia or optic disease; 2.25:
monoparesis; 2.5: paraparesis or sensory loss; 3: paraplegia or
hemiplegia. Body weights were measured three times per week
and prior to each MRI, marmosets were subject to a neurologic
exam performed by a neurologist.
Sample collection and DNA extraction
Marmosets were anesthetized with ketamine (10 mg/kg) intra-
muscularly prior to blood sampling. Approximately 1 cc blood was
drawn from the femoral triangle of each animal prior to HHV-6
inoculation and every two weeks post-inoculation. PBMC were
isolated using Lymphocyte Separation Medium (Mediatech, VA)
and plasma was collected from the isolation. Saliva was collected
at the time of blood sampling using gauze to swab the mouth of the
animal. Saliva was diluted with PBS and spun out of the gauze for
DNA extraction. DNA extraction from PBMC, plasma, saliva and
organs collected at euthanasia was performed with the DNeasy
Blood and Tissue DNA extraction kit (Qiagen, CA). DNA
extraction from 10 mM scrolls from paraffin-embedded brain
and spinal cord sections was performed with the QIAamp DNA
formalin fixed paraffin embedded (FFPE) tissue kit (Qiagen, CA).
HHV-6-specific PCR
Nested PCR (nPCR) was used to monitor the presence of HHV-
6 DNA in the plasma, PBMC and saliva every two weeks, as well
as in the organs and paraffin-embedded sections following
necropsy. HHV-6 nPCR was performed with primers against
the U57 region (major capsid protein, MCP) of the viral genome,
as described previously [20]. As this method does not distinguish
between HHV-6A and HHV-6B, sequencing was conducted at
the NINDS DNA sequencing facility (Bethesda, MD) to determine
the species present in the PCR positive samples. All reactions were
performed in triplicate, and PCR positive was defined as a positive
result two out of three times. All extracted samples were tested for
the presence of amplifiable DNA through the amplification of b-
actin using real-time PCR [47]. For the paraffin-embedded CNS
tissue, one 10 mM scroll was isolated from each section for DNA
extraction. Only samples with amplifiable DNA, as defined by b-
actin Ct values #35, were further analyzed for the presence of
HHV-6 DNA (.97% of all samples tested).
Detection of anti-HHV-6 IgG and IgM
Plasma antibodies against HHV-6 proteins were measured
every two weeks for 25 weeks post-inoculation using electro-
chemiluminescence technology (MSD, Gaithersburg, MD) devel-
oped in our laboratory [49]. HHV-6A or mock-infected (SupT1)
cell lysate, prepared as previously described [24], was spotted onto
high bind plates and allowed to dry overnight at room temperature
(RT). Plasma samples were diluted in MSD Antibody Diluent
(final dilution 1:10) and added to plates. Sulfo-Tag-labeled anti-
human IgG (Jackson ImmunoResearch) was used to detect IgG
responses and Sulfo-Tag-labeled polyclonal anti-human IgM
(MSD) was used to detect IgM responses. Each sample was tested
Table 1. Marmoset demographics and summary of results by experimental group.
Experimental group Marmoset
Sex/Age at study
start (months)
Time to clinical
symptoms (days)
Time between viral
inoculation and
sacrifice (months)
CNS samples positive
for HHV-6 DNA/total
surveyed
CNS region(s) positive
for HHV-6 DNA
HHV-6A intravenous M01* F/173 49 14 0/9
M02* F/45 29 12 0/10
M03* M/109 64 14 0/10
M04* M/28 27 14 1/9 N Occipital cortex/cerebellum
HHV-6B intravenous M05* M/99 – 8.5 1/10 N Occipital cortex/
cerebellum/brain stem
M06 M/147 –
M07* F/47 – 9 4/10 N Occipital cortex/cerebellum
N Prefrontal cortex
N Basal ganglia
N Cervical/thoracic spinal cord
M08* F/42 – 16 0/8
Vehicle Control
intravenous
M09 F/29 –
M10 F/29 –
M11 F/20 –
HHV-6A intranasal M12* M/55 – 6.5 0/11
M13 F/66 –
M14 F/53 –
M15 M/47 –
Total: 6/77 (8%)
doi:10.1371/journal.ppat.1003138.t001
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units. Results are corrected for responses to uninfected SupT1
lysates and reported as fold increases over baseline (before viral
inoculation).
In vivo magnetic resonance imaging (MRI)
MRI scans of the brain were performed monthly following viral
inoculation, and scans obtained during the experimental moni-
toring period were compared to baseline scans (conducted before
viral inoculation). Before each MRI experiment, marmosets were
fasted for 12 h, sedated with an intramuscular injection of 10 mg/
kg ketamine and orally intubated. Throughout the imaging
session, sedated marmosets were mechanically ventilated with a
mixture of oxygen and 1.25–2% isoflurane, and physiological
parameters including end-tidal CO2, heart rate, and SPO2 were
monitored using a capnograph and pulse oximeter (Surgivet,
Waukesha, WI, USA). Rectal temperature was also monitored,
and maintained at 38.5uC with a water heating pad.
MRI was performed on a 7 T/30 cm USR/AVIII MRI
scanner (BrukerBiospin Corp., Ettlingen, Germany) equipped with
a 15 cm gradient set of 450 mT/m strength (Resonance Research
Inc., Billerica, MA, USA). A custom-built, 16-rung, high-pass
birdcage radiofrequency coil with a 12 cm inner diameter was
used for transmission and a custom-built five-element receive-only
phased array equipped with preamplifiers was used for reception.
For all marmosets, the MRI protocol included T2-weighted Turbo
Spin Echo (T2w-TSE), T1-weighted Magnetization Prepared
Rapid Acquisition Gradient Echo (T1w-MPRAGE) and T1-
weighted Fast Low Angle Shot imaging (T1w-FLASH) performed
before the injection of contrast agent. A tail vein was cannulated
for the administration of a bolus of Gadolinium-Diethylene-
Triamine Penta-acetic Acid (Gd-DTPA; Magnevist). Each mar-
moset received 0.3 mMol/kg of Gd-DTPA over three minutes.
T1w-FLASH imaging was repeated approximately 20 minutes
after the injection of Gd-DTPA.
Post-mortem magnetic resonance imaging (MRI)
At necropsy, animals were transcardially perfused with cold 4%
paraformaldehyde (PFA) and whole brain and spinal cord were
collected. The brain was placed in 10% neutral buffered formalin
(NBF), and the spinal cord was cut into superior and inferior
sections and then placed in 4% PFA. Tissue sections were
submerged in nonmagnetic oil (Fomblin), and postmortem MR
images were recorded in the same magnet using a volume
transmit-receive RF coil with 40 mm diameter (Bruker-Biospin).
For all marmosets, the post-mortem brain MRI protocol included
T2w-TSE and T2*-weighted Multi Gradient Echo imaging (T2*-
MGE). The spinal cord post-mortem imaging protocol included
T2* weighted Fast Low Angle Shot Imaging (T2*-FLASH).
Immunohistochemistry (IHC) and histological staining of
CNS tissue
All animals were necropsied within 1 hour of death. Brains and
spinal cords were fixed in 10% NBF and 4% PFA, respectively,
and subsequently embedded in paraffin, sectioned at 5 mm and
stained using hematoxylin and eosin (HE). Two special stains,
Bielschowski’s method for neurofibrils and luxol fast blue (LFB) for
myelin, were additionally performed on all sections.
Standard immunoperoxidase IHC for ionized calcium binding
adapter molecule one (Iba-1), a macrophage and microglia-
specific marker, was also performed. Sections of brain and spinal
cord were deparaffinized, rehydrated, and blocked with 3%
hydrogen peroxide in PBS. Iba-1 pretreatment involved micro-
waving for 20 minutes in 0.01 citrate buffer, followed by
20 minutes of cooling. Following pretreatment, an avidin-biotin
block (Invitrogen Corporation, Frederick, MD, USA) and a Dako
Protein block (10 minutes; Carpineria, CA, USA) were conduct-
ed on all sections. A wash of tris-buffered saline (TBS) followed
each step.
Sections were incubated with Iba-1 (Wako Pure Chemical
Industries, Ltd., Osaka, Japan; polyclonal) at a 1:1000 dilution for
thirty minutes at RT. Slides were then incubated with a secondary
antibody, biotinylated goat anti-rabbit (Vector Laboratories,
Burlingame, CA, USA) at a 1:200 dilution for 30 minutes at
RT, followed by 30 minutes incubation at RT with Vectastain
ABC Elite (Vector Laboratories, Burlingame, CA, USA). Antigen-
antibody complex formation was detected using diaminobenzidine
(DAB; DakoCyomation, Carpinteria, CA, USA) and counter-
stained with Mayer’s hematoxylin. Irrelevant, isotype-matched
primary antibodies were used in place of the test antibody as
negative controls. Positive control tissue consisted of rhesus
macaque spleen.
Results
Intravenous inoculation of HHV-6A results in neurologic
symptoms
In our initial experiment, eight marmosets were inoculated
intravenously with HHV-6A (n=4) or HHV-6B (n=4). Each
marmoset received four inoculations, and daily monitoring was
conducted for 180 days from the first inoculation.
Shortly after the second intravenous inoculation of HHV-6A,
neurologic symptoms developed in two of the four marmosets,
M01 and M04 (Figure 1, solid lines). M01 presented with sensory
and motor impairment in her left arm, characterized by flapping,
which persisted for 29 days and then resolved (clinical score: 2.5).
M04 first presented with a facial palsy characterized by a droopy
lower lip and an inability to blink the eye on the affected side,
which persisted for seven days and then resolved (clinical score:
1.5). M04 then presented with motor impairment in his left leg,
holding it in retraction while moving. This lasted for 63 days and
then resolved, but a recurrence of weakness in this leg was noted
on day 167 post-inoculation and persisted through the end of the
monitoring period (clinical score: 2.5).
Following the third intravenous inoculation of HHV-6A, M03
presented with abnormal sitting behaviors, in which he would keep
one or both feet from touching the cage bottom when at rest
(clinical score: 2.5). Neurological exams revealed diminished
sensation in all extremities, and he failed to respond to hot or
cold stimuli. M02 exhibited more minor disease symptoms (clinical
score: 0.5) (Figure 1).
Though neurologic symptoms were observed in three of the four
marmosets inoculated intravenously with HHV-6A, intravenous
inoculation with HHV-6B did not result in clinical symptoms,
similar to the SupT1 control inoculations. In mouse and marmoset
models of EAE, weight loss is a surrogate marker of disease [50].
In our experiment, all marmosets were weighed several times per
week, but none exhibited weight loss over the 25-week monitoring
period (Figure 1, dashed lines).
MRI in HHV-6 infected marmosets
All marmosets underwent MRI scans of the brain before viral
inoculations, which served as the baseline control for each animal.
Following HHV-6 inoculation, all animals were scanned monthly
to assess radiologic changes from their baseline scan. As shown in
Figure 2, bilateral, T2-hyperintense lesions were noted in the
corpus callosum of one marmoset inoculated with HHV-6A
Novel Marmoset Model of HHV6A and HHV6B Infections
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tion (Figure 2A) were noted on consecutive slices of scans
conducted 173 days (Figure 2B) and 194 days (Figure 2C) post-
inoculation. The lesions had resolved by the time of the post-
mortem scan, which was conducted 433 days post-inoculation
(Figure 2D). On day 167 post-inoculation, M04 experienced a
recurrence of motor weakness in his hind limbs, corresponding to
a score of 2.5 (Figure 1, solid line). This deficit was still present on
days 173 and 194, when the brain abnormalities were detected.
No MRI-detectable lesions were observed in the brains of the
HHV-6B inoculated animals, comparable to the SupT1 vehicle
controls.
Figure 1. Marmosets inoculated intravenously with HHV-6A exhibited clinical symptoms without weight loss. Percent weight change
is on the left y-axis (dashed line). Clinical score is on the right y-axis (solid line). The scoring system is as follows, 0: no clinical signs, 0.5: apathy or
altered walking pattern without ataxia, 1: lethargy or tremor, 2: ataxia or optic disease, 2.25: monoparesis, 2.5: paraparesis or sensory loss, 3:
paraplegia or hemiplegia. Arrows represent times of HHV-6A intravenous inoculations.
doi:10.1371/journal.ppat.1003138.g001
Figure 2. Bilateral hyperintense MRI signal in corpus callosum of M04 (red arrows), inoculated with HHV-6A intravenously. (a)
Baseline, acquired before viral inoculation, (b) 183 days post-inoculation, (c) 194 days post-inoculation, (d) post-mortem scan (433 days post-
inoculation).
doi:10.1371/journal.ppat.1003138.g002
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specific IgM and IgG responses
Marmoset plasma was collected prior to HHV-6 inoculation
and every two weeks post inoculation, to monitor longitudinal IgM
and IgG reactivity to HHV-6 and SupT1 control lysates.
Intravenous inoculation of HHV-6A led to a rapid, virus-specific
IgM response that was detectable as early as week one post-
inoculation (Figure 3A). Over the 25 week monitoring period,
three of the four marmosets exposed to HHV-6A intravenously
produced HHV-6-specific IgM responses greater than two-fold
above baseline (M01, M02 and M04, Figure 3A), and all four
mounted HHV-6-specific IgG responses (Figure 3C) that were
detectable as early as week three post-inoculation.
By contrast to what we observed in the HHV-6A intravenously
inoculated marmosets, none of the marmosets inoculated
intravenously with HHV-6B mounted virus-specific IgM respons-
es (Figure 3B), and only two of the four demonstrated virus-
specific IgG responses (Figure 3D). M05 mounted a robust virus-
specific IgG response, the magnitude of which, in the absence of a
detectable IgM response, suggests a previous exposure to this
virus. M07 also mounted an IgG response, though lower in
magnitude than M05 (Figure 3D). The virus-specific IgM
(Figure 3B) and IgG (Figure 3D) responses of the remaining
two HHV-6B intravenously inoculated marmosets, M06 and
M08, increased less than two-fold over baseline, and were
therefore considered negative. SupT1 control marmosets did not
generate a virus-specific antibody response (data not shown).
Collectively, these results demonstrate that among the intrave-
nously inoculated marmosets, animals inoculated with HHV-6A
mounted greater IgM and IgG responses compared to animals
inoculated with HHV-6B, although these differences did not
reach statistical significance (Figure 4A). This may be due to the
small numbers of animals per group, a common limitation in
NHP studies, or the heterogeneity between marmosets, which is
inherent to this outbred model.
HHV-6 DNA detection in HHV-6 intravenously inoculated
marmosets
In marmosets inoculated with HHV-6A or HHV-6B intrave-
nously, viral DNA was detected infrequently in the plasma, PBMC
or saliva during the 25-week monitoring period (Figure 5). Viral
DNA was detected in two of the marmosets inoculated with HHV-
6A,atthreeweeksinthe plasmaand nine weeksinthesalivaofM03,
and at 21 weeks in the PBMC of M04. Viral DNA was also detected
in one marmoset inoculated with HHV-6B, at three weeks in the
PBMC and plasma of M08 (Figure 5). None of the vehicle control
marmosets tested positive for HHV-6 DNA (data not shown).
At euthanasia, the spleen, cervical lymph nodes (LN), olfactory
bulb, heart, kidney and liver were collected and analyzed for the
presence of HHV-6 DNA. Viral DNA was detected by nPCR in
the tissues of two of the four euthanized HHV-6A animals, but
none of the three HHV-6B euthanized animals. HHV-6 DNA was
detected in the spleen of M02 and in all analyzed tissues of M03,
and confirmed as HHV-6A by sequencing (data not shown).
Absence of clinical symptoms and antibody responses
when HHV-6A inoculated intranasally
As intravenous inoculation of HHV-6A but not HHV-6B led to
neurologic symptoms, we similarly characterized another group of
marmosets that we inoculated with HHV-6A intranasally, which
represents a more physiologic route of infection. Intranasal
inoculation was examined based on the recent report that
HHV-6 DNA could be detected in human nasal mucus and
olfactory bulb [51], suggesting the olfactory pathway as a route of
transmission for this virus. As salivary glands are a known reservoir
of HHV-6 and other herpesviruses [52,53], the nasal cavity may
also serve as a reservoir for HHV-6.
Four naı ¨ve marmosets were inoculated with HHV-6A intrana-
sally (Table 1) and monitored daily as previously described.
During the 25-week study period, none presented with clinical
signs of disease, in contrast to marmosets inoculated intravenously
with this virus (Figure 1). Interestingly, unlike marmosets
Figure 3. HHV-6-specific serum antibody responses of intravenously inoculated marmosets. Marmosets inoculated intravenously with
HHV-6A generated greater virus-specific IgM and IgG responses than marmosets inoculated intravenously with HHV-6B. Plasma collected every two
weeks was assayed for IgM and IgG reactivity to HHV-6 lysates. Results are represented as fold increases over baseline (before viral inoculation). The
dotted line marks a two-fold increase above baseline, responses below which were considered negative. (A) IgM and (C) IgG responses of HHV-6A
intravenously inoculated animals. (B) IgM and (D) IgG responses of HHV-6B intravenously inoculated animals.
doi:10.1371/journal.ppat.1003138.g003
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with HHV-6A intranasally failed to generate virus-specific IgM
(Figure 6A) or IgG antibody responses (Figure 6B); all detectable
serum antibodies were less than two fold above baseline
throughout the 25-week study period. The HHV-6-specific IgM
and IgG responses of intravenously inoculated marmosets were
significantly higher compared to those of intranasally inoculated
marmosets (Figure 4B).
HHV-6A DNA detected frequently in the periphery of
marmosets inoculated intranasally
Unlike marmosets inoculated with HHV-6A intravenously,
marmosets inoculated with HHV-6A intranasally routinely tested
positive for viral DNA in the saliva, PBMC and plasma (Figure 5).
Viral DNA was detected with increasing frequency as a function of
the inoculations. By week 11 (after the third and final inoculation
at week 8), HHV-6A DNA was detected consistently in all
marmosets, with an apparent increase during weeks 13–15 and
weeks 23–25, during which viral DNA was detected in multiple
compartments of most marmosets (Figure 5). The frequency of
marmosets testing positive over the 25-week period was signifi-
cantly elevated in the intranasally inoculated group compared to
the intravenously inoculated group (Figures 4C and 4D). M15 was
sacrificed for analysis as a representative of the HHV-6A
intranasal group, but viral DNA was not detected in his spleen,
cervical LN, olfactory bulb, heart, kidney or liver (data not shown).
Histopathological findings
Histological evaluation of the spinal cord and brain sections
showed limited pathology in M03 and M04, both of which were
intravenously inoculated with HHV-6A. Iba-1 IHC showed
multifocal macrophage/microglia nodules in the cervical spinal
cord of M03 (Figure 7A) and mild, multifocal, gliosis in the
thoracic and lumbar spinal cord of M04 (Figures 7D, 7E).
Increased expression of Iba-1 is a nonspecific response to tissue
injury and indicates activation of macrophages or microglia, the
resident macrophages of the CNS. Macrophageal/microglial
activation can be induced in the context of viral infection but is
generally associated with CNS injury or disease.
LFB and Bielschowski’s silver stain demonstrated mild myelin
abnormalities in M03, including focal areas of swollen myelin
sheaths (Figures 7B and 7C). In M04, LFB staining of the dorsal
root ganglion (Figure 7F) showed variation in myelin sheath size
and an abnormally high number of cells in the extracellular
matrix, suggesting gliosis. The arrow in Figure 7F denotes a region
of focal central neuronal chromatolysis, which is indicative of mild
reversible damage. Histological staining of other study subjects did
not reveal significant pathology. As euthanasia and subsequent
histological examination of the tissues was performed between 136
and 433 days post-inoculation, lesions reflective of the clinical signs
observed during the study may have evolved and undergone repair
and healing by the time of sacrifice.
HHV-6 DNA detected in the CNS of intravenously
inoculated marmosets
Brains and spinal cords of all euthanized animals (M01–M04,
M05, M06, M07, M12) were embedded in paraffin wax and
sectioned, and DNA was isolated and PCR amplified for HHV-6
sequences. Of the 77 total scrolls surveyed, six (8%) were PCR
positive for HHV-6 DNA (Table 1). The positive scrolls were from
Figure 4. Differences in HHV-6-specific antibody responses and detection of viral DNA between experimental groups. (A)
Comparison of virus-specific IgM and IgG responses between HHV-6A and HHV-6B-intravenously inoculated (iv) marmosets. AUC is calculated from
Figure 3. (B) Significantly elevated virus-specific IgM and IgG responses in marmosets inoculated with HHV-6A intravenously compared to marmosets
inoculated with HHV-6A intranasally (p=0.0286, Mann Whitney U test). AUC is calculated from Figures 3, 5. (C, D) The number of marmosets testing
positive for viral DNA was significantly greater in the HHV-6A intranasal group compared to the HHV-6A intravenous group (p=0.003, Mann Whitney
U test). AUC in (D) is calculated from (C). AUC: Area under the curve.
doi:10.1371/journal.ppat.1003138.g004
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one that was inoculated with HHV-6A intravenously (M04), and
two that were inoculated with HHV-6B intravenously (M05 and
M07). One brain region from M04 and one from M05 were
positive for viral DNA, while one spinal and three brain regions
from M07 were positive. Interestingly, portions of the occipital
cortex and cerebellum were positive in all three animals (Table 1).
These results demonstrate that in a subset of HHV-6 intravenously
inoculated marmosets, viral DNA can be detected in paraffin-
embedded CNS tissue up to 14 months (in the case of M04)
following intravenous viral inoculation.
Discussion
Though highly homologous at the nucleotide level, HHV-6A
and HHV-6B were recently classified as two separate viral species
due to distinct biological features and disease associations
(International Committee on Taxonomy of Viruses, 2011). We
investigated the outcome of unique HHV-6A and HHV-6B
infections in common marmosets, which are especially appropri-
ate for the study of a virus implicated in neurologic conditions
due to their natural susceptibility to infection [36], genetic and
immunologic proximity to humans, and suitability for MRI
monitoring [39]. Despite the association of HHV-6A with
neurologic disease, the time of exposure, route of infection and
related symptoms are largely unknown, partly because to our
knowledge, there are no serologic assays able to distinguish
between HHV-6A and HHV-6B. This marmoset model of
infection therefore represents a unique opportunity to study the
biology of HHV-6A infection and the mechanisms underlying its
associations with the CNS.
As the human herpesviruses 6A and 6B are implicated in several
CNS diseases, a non-human primate model of these viruses can be
utilized to investigate how this virus may contribute to disease, and
to test anti-viral therapies. For example, to date, there are no
antivirals specific for HHV-6 despite widespread consensus that it
is a clinically relevant pathogen. Yalcin et al. [54] followed
cynomologus and African green monkeys for 33 days following
subcutaneous or intravenous inoculation of HHV-6B. By contrast,
we followed marmosets for more than 180 days following
intravenous inoculations of HHV-6A and HHV-6B and intranasal
inoculations of HHV-6A. As small non-human primates, marmo-
sets present unique practical advantages compared to larger non-
human primates such as cynomologus and African greens. Similar
to Yalcin et al., we did not observe fever in any of the marmosets
following the HHV-6 inoculations. Yalcin et al. observed a rash on
the trunk of one African green monkey following subcutaneous
inoculation with HHV-6B. We did not observe rashes in any of the
marmosets inoculated with HHV-6B. These different observations
may be attributed biological differences between the non-human
primate species or differences between the routes of viral
inoculation performed in each study.
Figure 5. Longitudinal profiling of marmoset PBMC, plasma and saliva for HHV-6 DNA following viral inoculation. Compartments
listed in shaded boxes were positive for HHV-6 DNA by nested PCR at the indicated time points post-viral inoculation. The shading intensity
corresponds to the number of positive compartments. A blank box indicates that HHV-6 DNA was not detected in PBMC, plasma or saliva. Arrows
indicate times of viral inoculation, and the asterisk indicates that the fourth inoculation was specific to the HHV-6A and HHV-6B intravenous groups.
doi:10.1371/journal.ppat.1003138.g005
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cells, such as astrocytes [55,56], oligodendrocytes [57,58] and
neural stem cells [59]. However, HHV-6A replicates and produces
cytopathic effects with a greater efficiency in these cell types
compared to HHV-6B. If such in vitro results reflect the pattern of
HHV-6 infection in vivo, then HHV-6A may be the more involved
species in CNS infections [46,58]. Interestingly, there are data
supporting the prevalence of HHV-6A in healthy CNS, which
suggests that this virus may be a commensal of the brain in some
instances. In a survey of healthy brains from autopsy cases, Cuomo
et al. reported 32% positivity for HHV-6 DNA, with HHV-6A
found three times more frequently than HHV-6B [16]. In a study
of the ex vivo lymphoproliferative responses of MS patients, Soldan
et al. reported a high percentage of MS patients (relative to healthy
controls) with responses to HHV-6A, and a comparable number of
patients and controls with responses to HHV-6B [24], which
suggests a more prominent role for HHV-6A in this inflammatory
disease of the CNS.
The results of this study lend further support to the hypothe-
sized enhanced neuropathogenicity of HHV-6A compared to
HHV-6B. In the marmoset model described here, clear neurologic
symptoms were evident in three of four HHV-6A intravenously
inoculated animals, characterized by gait disturbance (M04),
sensory loss (M03) and incoordination (M01). By contrast, none of
the HHV-6B inoculated animals exhibited symptoms. Further-
more, brain abnormalities by MRI were noted in the corpus
callosum of one HHV-6A inoculated marmoset (M04), approxi-
mately two weeks following his second onset of unilateral hind
limb weakness. As callosal projection neurons are considered
important for motor coordination [60], MRI-detectable abnor-
malities in this region may be consistent with the observed
unilateral motor deficit observed in M04.
Areas of abnormal CNS pathology were detected in two of the
marmosets that exhibited neurologic symptoms, M03 and M04,
mainly characterized by microgliosis (see Figure 7). Microglial
activation is suggestive of a viral etiology but can also be associated
Figure 6. Marmosets inoculated intranasally with HHV-6A did not generate virus-specific serum IgM or IgG responses. Plasma
collected every two weeks was assayed for IgM and IgG reactivity to HHV-6 lysates. Results are represented as fold increases over baseline (before
viral inoculation). The dotted line marks a two-fold increase above baseline, responses below which were considered negative. (A) IgM and (B) IgG
responses of HHV-6A intranasally inoculated animals.
doi:10.1371/journal.ppat.1003138.g006
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embedded CNS tissue, adjacent sections were analyzed for the
presence of viral DNA. In a subset of intravenously inoculated
animals, we detected a low frequency of HHV-6 DNA in CNS
tissue, demonstrating that viral DNA is present in the brain and
spinal cord up to 14 months following intravenous exposure. This
is consistent with reports from human studies, in which a low
frequency of HHV-6 DNA (26%) was amplified from paraffin-
embedded healthy control brain tissues, suggesting that HHV-6 is
able to gain access to and may become a commensal pathogen of
the CNS [28]. In this study, although the presence of detectable
neuropathology and viral DNA in CNS tissue did not appear to
correlate with clinical symptoms, this may be due to the length of
time between the observed symptoms and sacrifice (up to 14
months). Additionally, the peripheral nervous system may have
been affected, and its involvement was not detected during the
CNS analyses performed in this study. We believe there may be
additional pathology and detectable viral DNA if the animals are
sacrificed closer in time to their exhibited clinical symptoms, which
is under consideration for future studies.
As neurologic symptoms were observed only in the HHV-6A
intravenously inoculated group, and as we had sufficient animals
for one additional group of four, we chose to inoculate with HHV-
6A by a more physiologic route, intranasally. Recent work from
our laboratory demonstrated that HHV-6 infection may com-
monly occur intranasally, and that the olfactory pathway may
mediate viral entry into the CNS. We demonstrated a high
frequency of subjects with HHV-6 DNA in nasal mucus [51],
comparable to that found in saliva, which is considered an in vivo
reservoir of HHV-6 [52,53]. Additionally, in a survey of brain
regions from several autopsy cases, the olfactory bulb was among
those from which HHV-6 DNA was detected most often [51].
Moreover, a number of neurotropic viruses are known to infect the
CNS by transmission through the olfactory pathway [61]. Thus,
intranasal inoculation of HHV-6 likely represents a common mode
of natural infection in humans.
While anti-viral serum IgM and IgG responses were observed in
marmosets inoculated with HHV-6A intravenously, marmosets
inoculated with HHV-6A intranasally did not mount serum IgM
or IgG responses for the 25-week study duration. This result is
consistent with a report by Chang, et al. that an anti-KSHV
antibody response was more elevated and sustained in marmosets
infected intravenously with KSHV compared to marmosets
infected orally [43]. HHV-6 DNA was detected infrequently in
the PBMC, plasma or saliva of marmosets inoculated intrave-
nously, while it was detected significantly more frequently in
marmosets inoculated intranasally. This inverse correlation
between antibody production and circulation of viral DNA in
the periphery suggests that the absence of a specific host humoral
immune response results in failure to clear the virus. These
observations highlight the importance of the route of infection as a
determinant in establishing humoral immunity that may serve to
clear the virus. The cellular immune responses of all animals in
this study are currently under investigation.
While viral DNA was rarely detected in the periphery of
marmosets inoculated with HHV-6A intravenously, it was
Figure 7. Spinal cord pathology in two HHV-6A intravenously inoculated marmosets. Iba-1 is specific for microglia and macrophages,
Luxol Fast Blue (LFB) stains myelin and Bielschowski’s stains neurofibrils. Cervical spinal cord pathology of M03 includes (A) microglial/macrophageal
aggregates identified by Iba-1, and swollen myelin sheaths identified by (B) LFB and (C) Bielschowski’s. Spinal cord pathology of M04 includes
microglial/macrophageal aggregates identified by Iba-1 in the (D) thoracic and (E) lumbar spinal cord and (F) myelin abnormalities identified by LFB
in the dorsal root ganglia, specifically variations in sheath size and focal neuronal chromatolysis (black arrow), indicative of mild reversible damage.
doi:10.1371/journal.ppat.1003138.g007
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mounted a robust anti-HHV-6 IgG response, despite a weak IgM
response, and though HHV-6 DNA was detected only once each
in his plasma and saliva over the 25 week monitoring period, his
liver, heart, cervical LN, kidney, spleen and olfactory bulb were all
PCR positive. These data suggest that HHV-6 or other
herpesviruses that establish latent infections may persist in vivo
yet remain undetected in accessible compartments (such as, in this
study, saliva, PBMC and plasma). These findings are consistent
with a previous study in which low levels of HHV-6 DNA in the
cerebrospinal fluid (CSF) but elevated viral DNA levels in the
brain of bone marrow transplant recipients were reported.
Therefore, levels of viral DNA in accessible compartments such
as the serum and CSF may not accurately reflect the extent of viral
infection in less accessible compartments such as the brain [62].
Interestingly, marmosets that generated anti-viral antibodies
cleared the virus yet developed neurologic symptoms, while
marmosets that did not generate anti-viral antibodies, and failed to
clear the virus, displayed no symptoms. This observation is
reminiscent of human immune-mediated diseases in which the
effects of an immune response to the agent may be more damaging
than the effects of the agent alone, for example in persistent viral
infections resulting from the constant presence of viral antigen
[63]. Antiviral antibodies are implicated in immune-mediated
disease, and antiviral immune responses can initiate disease, for
example myelin destruction [64]. This is consistent with our
observation of mild myelin abnormalities in two of the marmosets
that exhibited both clinical symptoms and anti-HHV-6 antibody
responses (M03 and M04).
Collectively, these observations help to define the contributions
of ubiquitous herpesviruses in the development of neurologic
disease in a non-human primate model. As little is known about
the acquisition and host response to HHV-6A and this species of
HHV-6 has comparatively greater associations with neurologic
disease, this non-human primate model of infection may further
our understanding about how this ubiquitous virus may trigger or
potentiate disease. More broadly, this in vivo model of HHV-6
infection can be used for preclinical testing of interventional
strategies to interfere with the virus and further elucidate its role in
human neurologic disease.
Accession numbers/ID numbers
The NCBI reference sequence NC_001664.2 was used for
HHV-6A. The NCBI reference sequence NC_000898.1 was used
for HHV-6B. The Entrez gene ID numbers for the genes
mentioned in the text are as follows, HHV-6A U90: 1487968;
HHV-6B U90: 1497087; HHV-6A U57: 1487939; HHV-6B U57:
1497059.
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